• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用氟替卡滨 PET 成像在体内确定阿尔茨海默病的 Tau 亚型。

Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging.

机构信息

Eli Lilly and Company, Indianapolis, IN, USA.

Avid Radiopharmaceuticals, Philadelphia, PA, USA.

出版信息

J Alzheimers Dis. 2019;71(3):1037-1048. doi: 10.3233/JAD-190264.

DOI:10.3233/JAD-190264
PMID:31476153
Abstract

At autopsy, individuals with Alzheimer's disease (AD) exhibit heterogeneity in the distribution of neurofibrillary tangles in neocortical and hippocampal regions. Subtypes of AD, defined using an algorithm based on the relative number of tangle counts in these regions, have been proposed-hippocampal sparing (relative sparing of the hippocampus but high cortical load), limbic predominant (high hippocampal load but lower load in association cortices), and typical (balanced neurofibrillary tangles counts in the hippocampus and association cortices) AD-and shown to be associated with distinct antemortem clinical phenotypes. The ability to distinguish these AD subtypes from the more typical tau signature in vivo could have important implications for clinical research. Flortaucipir positron emission tomography (PET) images acquired from 45 amyloid-positive participants, defined clinically as mild cognitive impairment or AD, aged 50-92 years, 56% female, and estimated to be Braak V-VI based on their PET pattern of tau pathology, were studied. By translating the neuropathologic algorithm to flortaucipir PET scans, patterns of tau pathology consistent with autopsy findings, and with a similar prevalence, were identified in vivo. 6/45 (13%) participants were identified as hippocampal sparing and 6/45 (13%) as limbic predominant AD subtypes. Hippocampal sparing participants were significantly younger than those assigned to the other two subtypes. Worse performance on delayed recall was associated with increased hippocampal tau signal, and worse performance on the trail making test B-A was associated with lower values of the hippocampus to cortex ratio. Prospective studies can further validate the flortaucipir SUVR cut-points and the phenotype of the corresponding AD subtypes.

摘要

在尸检中,阿尔茨海默病(AD)患者的神经纤维缠结在新皮质和海马区的分布存在异质性。使用基于这些区域中缠结计数相对数量的算法定义了 AD 的亚型-海马保留(海马相对保留,但皮质负荷高)、边缘优势(海马负荷高,但联合皮质负荷低)和典型(海马和联合皮质中的神经纤维缠结计数平衡)AD-并显示与独特的生前临床表型相关。能够将这些 AD 亚型与更典型的 tau 特征在体内区分开来,可能对临床研究具有重要意义。对 45 名淀粉样蛋白阳性参与者的氟脱氧葡萄糖正电子发射断层扫描(PET)图像进行了研究,这些参与者在临床上被定义为轻度认知障碍或 AD,年龄在 50-92 岁之间,56%为女性,根据他们的 tau 病理 PET 模式,估计处于 Braak V-VI 阶段。通过将神经病理学算法转换为氟脱氧葡萄糖 PET 扫描,体内识别出与尸检结果一致且具有相似患病率的 tau 病理模式。45 名参与者中有 6 名(13%)被确定为海马保留型 AD,6 名(13%)为边缘优势型 AD。海马保留型参与者明显比其他两种亚型的参与者年轻。延迟回忆表现较差与海马 tau 信号增加有关,而追踪测试 B-A 表现较差与海马与皮质比值较低有关。前瞻性研究可以进一步验证氟脱氧葡萄糖 SUVR 截止值和相应 AD 亚型的表型。

相似文献

1
Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging.使用氟替卡滨 PET 成像在体内确定阿尔茨海默病的 Tau 亚型。
J Alzheimers Dis. 2019;71(3):1037-1048. doi: 10.3233/JAD-190264.
2
18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.18F-氟托西匹 PET 与阿尔茨海默病和其他神经退行性疾病的尸检比较。
Brain. 2020 Dec 5;143(11):3477-3494. doi: 10.1093/brain/awaa276.
3
Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET.阿尔茨海默病中 18F 氟脱氧酪氨酸正电子发射断层扫描(18F Flortaucipir PET)评估的认知与神经病理 tau 之间的关系。
J Alzheimers Dis. 2021;80(3):1091-1104. doi: 10.3233/JAD-200808.
4
Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.正电子发射断层成像术(PET)[18F]氟替卡滨显像与阿尔茨海默病神经病理改变的死后评估。
JAMA Neurol. 2020 Jul 1;77(7):829-839. doi: 10.1001/jamaneurol.2020.0528.
5
Associations between quantitative [F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum.定量 [F]flortaucipir tau PET 与阿尔茨海默病谱中萎缩的相关性。
Alzheimers Res Ther. 2019 Jul 4;11(1):60. doi: 10.1186/s13195-019-0510-3.
6
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.神经病理学定义的具有不同临床特征的阿尔茨海默病亚型:一项回顾性研究。
Lancet Neurol. 2011 Sep;10(9):785-96. doi: 10.1016/S1474-4422(11)70156-9. Epub 2011 Jul 27.
7
Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.Flortaucipir F 18 Tau PET 显像剂的测试-重测可重复性。
J Nucl Med. 2018 Jun;59(6):937-943. doi: 10.2967/jnumed.117.200691. Epub 2017 Dec 28.
8
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.氟替卡匹尔PET tau蛋白结合与淀粉样蛋白负荷、临床诊断、年龄和认知之间的关系。
Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.
9
Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study.阿尔茨海默病病理定义亚型的神经影像学相关性:病例对照研究。
Lancet Neurol. 2012 Oct;11(10):868-77. doi: 10.1016/S1474-4422(12)70200-4. Epub 2012 Sep 3.
10
18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.18F-Flortaucipir PET 与阿尔茨海默病导致的轻度认知障碍患者的脑脊液、认知和神经影像学的相关性。
J Alzheimers Dis. 2020;74(2):589-601. doi: 10.3233/JAD-191330.

引用本文的文献

1
Establishing tau-PET cut-points for cognitive diagnosis with F-PI-2620 in a multi-ethnoracial cohort.在一个多族裔队列中使用F-PI-2620确定用于认知诊断的tau正电子发射断层扫描(PET)切点。
Imaging Neurosci (Camb). 2025 Jun 16;3. doi: 10.1162/IMAG.a.41. eCollection 2025.
2
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.阿尔茨海默病神经病理学及其通过体液和影像生物标志物进行的评估。
Mol Neurodegener. 2025 Mar 14;20(1):33. doi: 10.1186/s13024-025-00819-y.
3
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
淀粉样蛋白和tau蛋白PET的更新后合理使用标准:阿尔茨海默病协会与核医学和分子影像学会工作组的报告
Alzheimers Dement. 2025 Jan;21(1):e14338. doi: 10.1002/alz.14338. Epub 2025 Jan 8.
4
Divergent neurodegenerative patterns: Comparison of [F] fluorodeoxyglucose-PET- and MRI-based Alzheimer's disease subtypes.不同的神经退行性模式:基于[F]氟脱氧葡萄糖正电子发射断层扫描(PET)和磁共振成像(MRI)的阿尔茨海默病亚型比较。
Brain Commun. 2024 Nov 23;6(6):fcae426. doi: 10.1093/braincomms/fcae426. eCollection 2024.
5
Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease.血浆pTau217比值可预测淀粉样蛋白阳性的早期阿尔茨海默病患者大脑区域tau蛋白的持续积累。
Alzheimers Dement. 2025 Feb;21(2):e14411. doi: 10.1002/alz.14411. Epub 2024 Nov 22.
6
Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia.血管危险因素和脑血管病与无痴呆个体阿尔茨海默病病理改变的关联。
Neurology. 2024 Oct 8;103(7):e209801. doi: 10.1212/WNL.0000000000209801. Epub 2024 Sep 17.
7
Clinical Heterogeneity in Alzheimer's Disease: A Possible New Amnesic Phenotype.阿尔茨海默病的临床异质性:一种可能的新型失忆表型。
J Alzheimers Dis Rep. 2024 Jun 21;8(1):959-969. doi: 10.3233/ADR-230196. eCollection 2024.
8
Microglia measured by TSPO PET are associated with Alzheimer's disease pathology and mediate key steps in a disease progression model.TSPO PET 测量的小胶质细胞与阿尔茨海默病病理有关,并介导疾病进展模型中的关键步骤。
Alzheimers Dement. 2024 Apr;20(4):2397-2407. doi: 10.1002/alz.13699. Epub 2024 Feb 1.
9
CenTauR: Toward a universal scale and masks for standardizing tau imaging studies.CenTauR:迈向用于标准化tau成像研究的通用量表和掩膜。
Alzheimers Dement (Amst). 2023 Jul 7;15(3):e12454. doi: 10.1002/dad2.12454. eCollection 2023 Jul-Sep.
10
The Adult Neurogenesis Theory of Alzheimer's Disease.阿尔茨海默病的成人神经发生理论。
J Alzheimers Dis. 2023;93(4):1237-1276. doi: 10.3233/JAD-221279.